The latest price target for Quest Diagnostics (NYSE:DGX) was reported by Morgan Stanley on December 17, 2024. The analyst firm set a price target for $172.00 expecting DGX to rise to within 12 months (a possible 12.11% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Quest Diagnostics (NYSE:DGX) was provided by Morgan Stanley, and Quest Diagnostics upgraded their overweight rating.

The last upgrade for Quest Diagnostics Inc happened on December 17, 2024 when Morgan Stanley raised their price target to $172. Morgan Stanley previously had an equal-weight for Quest Diagnostics Inc.

The last downgrade for Quest Diagnostics Inc happened on May 2, 2023 when B of A Securities changed their price target from $166 to $148 for Quest Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a upgraded with a price target of $145.00 to $172.00. The current price Quest Diagnostics (DGX) is trading at is $153.42, which is within the analyst’s predicted range.